Email
Print
Influenza Vaccine Market – By Product Type , By Influenza Type , By Age Group , By Valency , By Frequency , By Distribution Channel , By Geography – Global Opportunity Analysis & Industry Forecast, 2024-2030
Influenza Vaccine Market Overview:
Influenza Vaccine Market Size is valued at $15.1 Billion by 2030, and is anticipated to grow at a CAGR of 9.4% during the forecast period 2024 -2030. The influenza vaccine market is experiencing significant growth and transformation due to several key trends. A primary trend is the increasing adoption of quadrivalent vaccines, which protect against four strains of the influenza virus, as opposed to the traditional trivalent vaccines. This shift enhances vaccine effectiveness and broadens immunity coverage. Another major trend is the rise of cell-based and recombinant DNA technologies in vaccine production, which offer faster and more flexible manufacturing compared to traditional egg-based methods. The COVID-19 pandemic has also influenced the influenza vaccine market, highlighting the importance of vaccination and boosting public awareness and government initiatives for flu vaccination programs.
Furthermore, there is an expanding focus on universal influenza vaccines, which aim to provide long-lasting protection against multiple influenza strains, reducing the need for annual vaccinations. Advances in vaccine delivery methods, such as nasal sprays and microneedle patches, are improving patient compliance and accessibility. Increased investments in research and development, along with collaborations between pharmaceutical companies and public health organizations, are also driving innovation in this market. Overall, these trends are poised to enhance the effectiveness, accessibility, and uptake of influenza vaccines globally.
Market Snapshot:
Influenza Vaccine Market - Report Coverage:
The “Influenza Vaccine Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Influenza Vaccine Market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COVID-19 / Ukraine Crisis - Impact Analysis:
- The COVID-19 pandemic has significantly impacted the Influenza Vaccine market, driving substantial changes in demand, production, and public health policies. The heightened awareness of respiratory illnesses and the importance of vaccination have led to increased uptake of flu vaccines as a preventive measure against potential coinfections. Governments and healthcare organizations have intensified their vaccination campaigns to mitigate the strain on healthcare systems already burdened by COVID-19. This surge in demand has necessitated scaling up production capabilities and improving supply chain logistics to ensure timely delivery and widespread availability of vaccines. Additionally, the pandemic has accelerated innovations in vaccine technology, with efforts to develop combined vaccines that target both COVID-19 and influenza. This integration aims to streamline immunization processes and enhance public health outcomes. Overall, the COVID-19 pandemic has underscored the critical role of vaccines in public health, driving a paradigm shift in how seasonal influenza vaccination is perceived and implemented globally.
- The Russo-Ukraine War has significantly impacted the Influenza Vaccine market by disrupting supply chains, diverting resources, and altering market dynamics. The conflict has led to logistical challenges in vaccine distribution, especially in affected regions, thereby reducing access to vaccines. Manufacturing facilities have faced interruptions, contributing to potential shortages and increased production costs. Furthermore, the reallocation of healthcare resources towards emergency medical needs and conflict-related healthcare services has shifted focus away from routine immunization programs. This diversion of attention has strained efforts to maintain high vaccination coverage rates, potentially leading to lower immunity levels against influenza. Additionally, geopolitical tensions have affected international collaborations and funding for vaccine research and distribution programs. The instability in the region has also influenced global markets, leading to increased prices and decreased availability of essential materials needed for vaccine production. Overall, the war has created a challenging environment for sustaining the influenza vaccine market, necessitating adaptive strategies to mitigate its impact and ensure continued public health protection.
Key Takeaways:
-
Growing Demand for Inactivated Influenza Vaccine
The demand for inactivated influenza vaccines is increasing due to enhanced standardization practices tailored to specific virus strains. These vaccines are formulated by growing virus strains in embryonated chicken eggs and purifying them through zonal centrifugation, ensuring high efficacy and safety. The meticulous standardization process, involving the development of new SRID reagents for each influenza strain, guarantees precise antigenic matching and effective immunization. A recent development of note is FLUCELVAX QUADRIVALENT, a cell-based influenza vaccine by Seqirus, which received FDA approval for use in children 6 months and older in June 2023, aimed at providing broader protection against multiple strains. Additionally, global health organizations have initiated campaigns to increase vaccination rates among high-risk groups, such as the elderly and healthcare workers, emphasizing the importance of timely immunization. The continuous evolution of influenza viruses necessitates ongoing research and adaptation, driving the market forward as manufacturers strive to keep pace with emerging strains.
-
Rising Incidence of Influenza
The consistent rise in influenza cases globally is a significant driver for the influenza vaccine market. Seasonal flu outbreaks affect millions annually, causing severe illness and death, particularly among high-risk groups like the elderly, children, and those with chronic health conditions. The increasing prevalence of influenza strains emphasizes the need for effective vaccination programs to reduce the disease burden and prevent epidemics. Annual vaccination is recommended by health authorities worldwide, underscoring the importance of maintaining high immunization rates. The rising awareness of the potential complications of influenza, including secondary bacterial infections and exacerbation of chronic diseases, further drives the demand for vaccines. Additionally, the emergence of new and more virulent strains necessitates ongoing vaccination efforts, reinforcing the critical role of flu vaccines in public health.
-
Growing Demand for Influenza Vaccine Due to Government Initiatives
Governments worldwide are actively promoting influenza vaccination through public health campaigns, subsidized vaccination programs, and funding for vaccine research and development. These initiatives aim to increase vaccination coverage rates, reduce healthcare costs associated with treating influenza, and prevent flu-related hospitalizations and deaths. Enhanced government support and policies are crucial in driving the market growth for influenza vaccines. For instance, national immunization programs often provide vaccines free of charge or at subsidized rates, making them accessible to a broader population. Governments also invest in educational campaigns to raise awareness about the importance of flu vaccination, targeting both the general public and healthcare professionals. Furthermore, public health policies mandating vaccination for certain groups, such as healthcare workers and children attending school, significantly boost vaccine uptake. Collaboration between governments, international organizations, and vaccine manufacturers ensures a coordinated approach to influenza prevention, further driving market growth.
-
Hesitancy and Misinformation surrounding vaccines
One of the most significant challenges in the influenza vaccine market is vaccine hesitancy, fueled by misinformation and misconceptions about vaccine safety and efficacy. Despite widespread public health campaigns, a substantial portion of the population remains skeptical about getting vaccinated due to fears of side effects, doubts about vaccine effectiveness, and general mistrust of pharmaceutical companies and health authorities. Social media and other online platforms can exacerbate the spread of misinformation, leading to decreased vaccination rates and undermining efforts to control influenza outbreaks. Addressing this challenge requires targeted education and communication strategies to build public trust and counteract misinformation, emphasizing the critical role of vaccination in preventing influenza-related morbidity and mortality.
Key Market Players:
Product launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Influenza Vaccine Market. The top 10 companies in this industry are listed below:
- GSK plc
- Sanofi S.A.
- AstraZeneca plc
- CSL Limited
- BIKEN Co., Ltd.
- Abbott Laboratories
- SINOVAC Biotech Ltd.
- Viatris Inc.
- Novartis Ag
- Moderna, Inc.
Scope of the Report:
List of Tables:
Table 1: Influenza Vaccine Market Overview 2023-2030
Table 2: Influenza Vaccine Market Leader Analysis 2023-2030 (US$)
Table 3: Influenza Vaccine Market Product Analysis 2023-2030 (US$)
Table 4: Influenza Vaccine Market End User Analysis 2023-2030 (US$)
Table 5: Influenza Vaccine Market Patent Analysis 2013-2023* (US$)
Table 6: Influenza Vaccine Market Financial Analysis 2023-2030 (US$)
Table 7: Influenza Vaccine Market Driver Analysis 2023-2030 (US$)
Table 8: Influenza Vaccine Market Challenges Analysis 2023-2030 (US$)
Table 9: Influenza Vaccine Market Constraint Analysis 2023-2030 (US$)
Table 10: Influenza Vaccine Market Supplier Bargaining Power Analysis 2023-2030 (US$)
Table 11: Influenza Vaccine Market Buyer Bargaining Power Analysis 2023-2030 (US$)
Table 12: Influenza Vaccine Market Threat of Substitutes Analysis 2023-2030 (US$)
Table 13: Influenza Vaccine Market Threat of New Entrants Analysis 2023-2030 (US$)
Table 14: Influenza Vaccine Market Degree of Competition Analysis 2023-2030 (US$)
Table 15: Influenza Vaccine Market Value Chain Analysis 2023-2030 (US$)
Table 16: Influenza Vaccine Market Pricing Analysis 2023-2030 (US$)
Table 17: Influenza Vaccine Market Opportunities Analysis 2023-2030 (US$)
Table 18: Influenza Vaccine Market Product Life Cycle Analysis 2023-2030 (US$)
Table 19: Influenza Vaccine Market Supplier Analysis 2023-2030 (US$)
Table 20: Influenza Vaccine Market Distributor Analysis 2023-2030 (US$)
Table 21: Influenza Vaccine Market Trend Analysis 2023-2030 (US$)
Table 22: Influenza Vaccine Market Size 2023 (US$)
Table 23: Influenza Vaccine Market Forecast Analysis 2023-2030 (US$)
Table 24: Influenza Vaccine Market Sales Forecast Analysis 2023-2030 (Units)
Table 25: Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 26: Influenza Vaccine Market By Vaccine Type, Revenue & Volume, By Injection, 2023-2030 ($)
Table 27: Influenza Vaccine Market By Vaccine Type, Revenue & Volume, By Nasal Spray, 2023-2030 ($)
Table 28: Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 29: Influenza Vaccine Market By Target Group, Revenue & Volume, By Infants, 2023-2030 ($)
Table 30: Influenza Vaccine Market By Target Group, Revenue & Volume, By Children, 2023-2030 ($)
Table 31: Influenza Vaccine Market By Target Group, Revenue & Volume, By Adults, 2023-2030 ($)
Table 32: Influenza Vaccine Market By Target Group, Revenue & Volume, By Pregnant Women, 2023-2030 ($)
Table 33: Influenza Vaccine Market By Target Group, Revenue & Volume, By Elderly People, 2023-2030 ($)
Table 34: North America Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 35: North America Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 36: South america Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 37: South america Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 38: Europe Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 39: Europe Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 40: APAC Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 41: APAC Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 42: Middle East & Africa Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 43: Middle East & Africa Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 44: Russia Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 45: Russia Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 46: Israel Influenza Vaccine Market, Revenue & Volume, By Vaccine Type, 2023-2030 ($)
Table 47: Israel Influenza Vaccine Market, Revenue & Volume, By Target Group, 2023-2030 ($)
Table 48: Top Companies 2023 (US$)Influenza Vaccine Market, Revenue & Volume
Table 49: Product Launch 2023-2030Influenza Vaccine Market, Revenue & Volume
Table 50: Mergers & Acquistions 2023-2030Influenza Vaccine Market, Revenue & Volume
List of Figures:
Figure 1: Overview of Influenza Vaccine Market 2023-2030
Figure 2: Market Share Analysis for Influenza Vaccine Market 2023 (US$)
Figure 3: Product Comparison in Influenza Vaccine Market 2023-2030 (US$)
Figure 4: End User Profile for Influenza Vaccine Market 2023-2030 (US$)
Figure 5: Patent Application and Grant in Influenza Vaccine Market 2013-2023* (US$)
Figure 6: Top 5 Companies Financial Analysis in Influenza Vaccine Market 2023-2030 (US$)
Figure 7: Market Entry Strategy in Influenza Vaccine Market 2023-2030
Figure 8: Ecosystem Analysis in Influenza Vaccine Market 2023
Figure 9: Average Selling Price in Influenza Vaccine Market 2023-2030
Figure 10: Top Opportunites in Influenza Vaccine Market 2023-2030
Figure 11: Market Life Cycle Analysis in Influenza Vaccine Market
Figure 12: GlobalBy Vaccine TypeInfluenza Vaccine Market Revenue, 2023-2030 ($)
Figure 13: GlobalBy Target GroupInfluenza Vaccine Market Revenue, 2023-2030 ($)
Figure 14: Global Influenza Vaccine Market - By Geography
Figure 15: Global Influenza Vaccine Market Value & Volume, By Geography, 2023-2030 ($)
Figure 16: Global Influenza Vaccine Market CAGR, By Geography, 2023-2030 (%)
Figure 17: North America Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 18: US Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 19: US GDP and Population, 2023-2030 ($)
Figure 20: US GDP – Composition of 2023, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2023-2030 ($)
Figure 22: Canada Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 23: Canada GDP and Population, 2023-2030 ($)
Figure 24: Canada GDP – Composition of 2023, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2023-2030 ($)
Figure 26: Mexico Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 27: Mexico GDP and Population, 2023-2030 ($)
Figure 28: Mexico GDP – Composition of 2023, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2023-2030 ($)
Figure 30: South America Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 31: Brazil Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 32: Brazil GDP and Population, 2023-2030 ($)
Figure 33: Brazil GDP – Composition of 2023, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2023-2030 ($)
Figure 35: Venezuela Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 36: Venezuela GDP and Population, 2023-2030 ($)
Figure 37: Venezuela GDP – Composition of 2023, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2023-2030 ($)
Figure 39: Argentina Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 40: Argentina GDP and Population, 2023-2030 ($)
Figure 41: Argentina GDP – Composition of 2023, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2023-2030 ($)
Figure 43: Ecuador Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 44: Ecuador GDP and Population, 2023-2030 ($)
Figure 45: Ecuador GDP – Composition of 2023, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2023-2030 ($)
Figure 47: Peru Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 48: Peru GDP and Population, 2023-2030 ($)
Figure 49: Peru GDP – Composition of 2023, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2023-2030 ($)
Figure 51: Colombia Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 52: Colombia GDP and Population, 2023-2030 ($)
Figure 53: Colombia GDP – Composition of 2023, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2023-2030 ($)
Figure 55: Costa Rica Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 56: Costa Rica GDP and Population, 2023-2030 ($)
Figure 57: Costa Rica GDP – Composition of 2023, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2023-2030 ($)
Figure 59: Europe Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 60: U.K Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 61: U.K GDP and Population, 2023-2030 ($)
Figure 62: U.K GDP – Composition of 2023, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2023-2030 ($)
Figure 64: Germany Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 65: Germany GDP and Population, 2023-2030 ($)
Figure 66: Germany GDP – Composition of 2023, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2023-2030 ($)
Figure 68: Italy Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 69: Italy GDP and Population, 2023-2030 ($)
Figure 70: Italy GDP – Composition of 2023, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2023-2030 ($)
Figure 72: France Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 73: France GDP and Population, 2023-2030 ($)
Figure 74: France GDP – Composition of 2023, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2023-2030 ($)
Figure 76: Netherlands Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 77: Netherlands GDP and Population, 2023-2030 ($)
Figure 78: Netherlands GDP – Composition of 2023, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2023-2030 ($)
Figure 80: Belgium Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 81: Belgium GDP and Population, 2023-2030 ($)
Figure 82: Belgium GDP – Composition of 2023, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2023-2030 ($)
Figure 84: Spain Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 85: Spain GDP and Population, 2023-2030 ($)
Figure 86: Spain GDP – Composition of 2023, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2023-2030 ($)
Figure 88: Denmark Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 89: Denmark GDP and Population, 2023-2030 ($)
Figure 90: Denmark GDP – Composition of 2023, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2023-2030 ($)
Figure 92: APAC Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 93: China Influenza Vaccine Market Value & Volume, 2023-2030
Figure 94: China GDP and Population, 2023-2030 ($)
Figure 95: China GDP – Composition of 2023, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2023-2030 ($)Influenza Vaccine Market China Export and Import Value & Volume, 2023-2030 ($)
Figure 97: Australia Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 98: Australia GDP and Population, 2023-2030 ($)
Figure 99: Australia GDP – Composition of 2023, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2023-2030 ($)
Figure 101: South Korea Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 102: South Korea GDP and Population, 2023-2030 ($)
Figure 103: South Korea GDP – Composition of 2023, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2023-2030 ($)
Figure 105: India Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 106: India GDP and Population, 2023-2030 ($)
Figure 107: India GDP – Composition of 2023, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2023-2030 ($)
Figure 109: Taiwan Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 110: Taiwan GDP and Population, 2023-2030 ($)
Figure 111: Taiwan GDP – Composition of 2023, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2023-2030 ($)
Figure 113: Malaysia Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 114: Malaysia GDP and Population, 2023-2030 ($)
Figure 115: Malaysia GDP – Composition of 2023, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2023-2030 ($)
Figure 117: Hong Kong Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 118: Hong Kong GDP and Population, 2023-2030 ($)
Figure 119: Hong Kong GDP – Composition of 2023, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2023-2030 ($)
Figure 121: Middle East & Africa Influenza Vaccine Market Middle East & Africa 3D Printing Market Value & Volume, 2023-2030 ($)
Figure 122: Russia Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 123: Russia GDP and Population, 2023-2030 ($)
Figure 124: Russia GDP – Composition of 2023, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2023-2030 ($)
Figure 126: Israel Influenza Vaccine Market Value & Volume, 2023-2030 ($)
Figure 127: Israel GDP and Population, 2023-2030 ($)
Figure 128: Israel GDP – Composition of 2023, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2023-2030 ($)
Figure 130: Entropy Share, By Strategies, 2023-2030* (%)Influenza Vaccine Market
Figure 131: Developments, 2023-2030*Influenza Vaccine Market
Figure 132: Company 1 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 133: Company 1 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 134: Company 1 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 135: Company 2 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 136: Company 2 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 137: Company 2 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 138: Company 3 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 139: Company 3 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 140: Company 3 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 141: Company 4 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 142: Company 4 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 143: Company 4 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 144: Company 5 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 145: Company 5 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 146: Company 5 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 147: Company 6 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 148: Company 6 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 149: Company 6 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 150: Company 7 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 151: Company 7 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 152: Company 7 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 153: Company 8 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 154: Company 8 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 155: Company 8 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 156: Company 9 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 157: Company 9 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 158: Company 9 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 159: Company 10 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 160: Company 10 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 161: Company 10 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 162: Company 11 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 163: Company 11 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 164: Company 11 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 165: Company 12 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 166: Company 12 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 167: Company 12 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 168: Company 13 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 169: Company 13 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 170: Company 13 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 171: Company 14 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 172: Company 14 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 173: Company 14 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
Figure 174: Company 15 Influenza Vaccine Market Net Revenue, By Years, 2023-2030* ($)
Figure 175: Company 15 Influenza Vaccine Market Net Revenue Share, By Business segments, 2023 (%)
Figure 176: Company 15 Influenza Vaccine Market Net Sales Share, By Geography, 2023 (%)
The Influenza Vaccine Market is projected to grow at 9.4% CAGR during the forecast period 2024-2030.
Influenza Vaccine Market size is estimated to surpass $15.4 billion by 2030 from $7.7 billion in 2023.
The leading players in the Influenza Vaccine Market are GSK plc, Sanofi S.A., AstraZeneca plc, CSL Limited, BIKEN Co. Ltd., and others.
Shift towards quadrivalent will shape the market in the future, as Quadrivalent vaccines protect against four different flu strains, providing broader coverage.\\\\r\\\\n\\\\r\\\\n
Government programs to expand vaccination coverage and the rising burden of influenza cases are expected to drive the market in the future.